ATXS
Price
$9.55
Change
+$0.10 (+1.06%)
Updated
Dec 20, 04:59 PM (EDT)
75 days until earnings call
SNDX
Price
$13.08
Change
+$0.23 (+1.79%)
Updated
Dec 20, 04:59 PM (EDT)
74 days until earnings call
Ad is loading...

ATXS vs SNDX

Header iconATXS vs SNDX Comparison
Open Charts ATXS vs SNDXBanner chart's image
Astria Therapeutics
Price$9.55
Change+$0.10 (+1.06%)
Volume$3.51K
CapitalizationN/A
Syndax Pharmaceuticals
Price$13.08
Change+$0.23 (+1.79%)
Volume$62.31K
CapitalizationN/A
ATXS vs SNDX Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. SNDX commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and SNDX is a Hold.

COMPARISON
Comparison
Dec 21, 2024
Stock price -- (ATXS: $9.57 vs. SNDX: $13.08)
Brand notoriety: ATXS and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 281% vs. SNDX: 248%
Market capitalization -- ATXS: $540.08M vs. SNDX: $1.12B
ATXS [@Biotechnology] is valued at $540.08M. SNDX’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 6 bearish.
  • SNDX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а +0.53% price change this week, while SNDX (@Biotechnology) price change was -6.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ATXS is expected to report earnings on Mar 06, 2025.

SNDX is expected to report earnings on Mar 05, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.12B) has a higher market cap than ATXS($540M). ATXS YTD gains are higher at: 24.609 vs. SNDX (-39.472). ATXS has higher annual earnings (EBITDA): -100.97M vs. SNDX (-296.86M). SNDX has more cash in the bank: 406M vs. ATXS (344M). SNDX has less debt than ATXS: SNDX (854K) vs ATXS (5.64M). SNDX has higher revenues than ATXS: SNDX (16M) vs ATXS (0).
ATXSSNDXATXS / SNDX
Capitalization540M1.12B48%
EBITDA-100.97M-296.86M34%
Gain YTD24.609-39.472-62%
P/E RatioN/AN/A-
Revenue016M-
Total Cash344M406M85%
Total Debt5.64M854K660%
FUNDAMENTALS RATINGS
ATXS vs SNDX: Fundamental Ratings
ATXS
SNDX
OUTLOOK RATING
1..100
6656
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5589
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (63) in the Biotechnology industry is in the same range as SNDX (85). This means that ATXS’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for ATXS (100). This means that SNDX’s stock grew somewhat faster than ATXS’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as SNDX (98). This means that ATXS’s stock grew similarly to SNDX’s over the last 12 months.

ATXS's Price Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for SNDX (89). This means that ATXS’s stock grew somewhat faster than SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for ATXS (100). This means that SNDX’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSSNDX
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 23 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 3 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
75%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CTOGX15.760.19
+1.22%
Calamos Timpani SMID Growth R6
PLCGX16.830.19
+1.14%
Principal LargeCap Growth I R6
MSCIX12.540.10
+0.80%
Madison Small Cap I
CDWAX10.630.04
+0.39%
American Funds Dvlpg Wld Gr&Inc 529A
PBEAX22.06N/A
N/A
PGIM Jennison Value A

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with IMNM. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.27%
IMNM - ATXS
43%
Loosely correlated
-0.81%
XENE - ATXS
42%
Loosely correlated
-0.54%
KYMR - ATXS
42%
Loosely correlated
+3.83%
ARVN - ATXS
41%
Loosely correlated
+3.65%
ACLX - ATXS
41%
Loosely correlated
+0.56%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with ARVN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then ARVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+1.79%
ARVN - SNDX
49%
Loosely correlated
+3.65%
ABOS - SNDX
48%
Loosely correlated
+2.22%
RAPT - SNDX
45%
Loosely correlated
+3.90%
VCYT - SNDX
45%
Loosely correlated
+4.66%
CRSP - SNDX
43%
Loosely correlated
+0.83%
More